LANADELUMAB (Takhyzro®)
Clinical Indication
Preventing recurrent attacks of hereditary angioedema
Comments
In line with NICE TA606
Date of classification
January 2020
Red
Medicines which should be prescribed only in a specialist setting usually within a secondary or tertiary care service. NB: Some highly specialised RED medicines e.g. injectable treatments for cancer are not included on the LLR APC website list.